$8.32
-0.18%LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโmonitor closely.
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
LFVN โข NASDAQ
| LifeVantage Corporation Cash Flow Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
9.8M | 2.9M | 2.5M | 3.1M | 3.1M | 11.5M | 7.4M | 5.8M | 1.6M | 6M | 7M | 11.4M | 7.6M | 12.5M | -50.8M | -11M | -9.1M | -2.1M | -3.7M | -2.7M | |
3.2M | 3.6M | 3.6M | 3.3M | 3.3M | 5.1M | 1.9M | 1.3M | 1.6M | 1.9M | 2.3M | 2.1M | 1.7M | 521.3K | 214.7K | 254.9K | 179.7K | 219.7K | 92.4K | 265.3K | |
-1.7M | -1.3M | -1.7M | -81K | -81K | 364K | 563K | 831K | -740K | -2.6M | 91K | 2.2M | -892K | -2.7M | 50.8M | 0.0 | 0.0 | -322.2B | 0.0 | 0.0 | |
5.7M | 3.3M | 3.2M | 1.8M | 1.8M | 4.9M | 5.5M | 3.2M | 2.6M | 2.6M | 1.8M | 3M | 2.2M | 1.3M | 766.5K | 2.7M | 1.5M | 322.2B | 0.0 | 0.0 | |
1.5M | 1.3M | 1.8M | 4M | 4M | 46K | 42K | 32K | 381K | 3.1M | 453K | 281K | 3.9M | 6.8M | 3.3M | 3.5M | 1.2M | 687.3K | 1.3M | 96.7K | |
(4.9M) | (2.3M) | (1.9M) | (0.0) | (0.0) | (1.6M) | (1.3M) | (2.9M) | (5.5M) | (1.4M) | -1.7M | -4.9M | -6.1M | -3.7M | -56K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-6.6M | 2.4M | -2.6M | -4.1M | -4.1M | -3.7M | 2.3M | 2.1M | 1.1M | -5.1M | 1.6M | -6.8M | -3.8M | 1M | 445.5K | 168.6K | 1.1M | 399.6K | -799.7K | 1.5M | |
11.9M | 12.2M | 6.8M | 8M | 8M | 18.3M | 17.8M | 13.3M | 6.6M | 6M | 13.2M | 12.1M | 10.7M | 19.4M | 4.7M | -4.5M | -5.2M | -747.8K | -3.1M | -915.6K | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.4M | -2.2M | -3.1M | -1.5M | -1.5M | -2.7M | -2.5M | -4.6M | -1.1M | -562K | -1.2M | -2.2M | -5.1M | -2.2M | -164K | -46.7K | -245.5K | -70.3K | -60.2K | -136.4K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -354.7B | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.5M | (0.0) | -3.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 350K | 75K | 225K | 450K | 425K | 3.1M | 0.0 | |
4K | 0.0 | 8K | 0.0 | 0.0 | -2.7M | -2M | -4.6M | -1.1M | -562K | -1.2M | -350K | -5.1M | -1.9M | -89K | 178.3K | 0.0 | 354.7B | 58.6K | -59.9K | |
-1.4M | -2.2M | -3.1M | -1.5M | -1.5M | -2.7M | -4.5M | -4.6M | -1.1M | -562K | -1.2M | -2.2M | -5.1M | -1.9M | -89K | (178.3K) | (204.5K) | -1.2M | (3.1M) | -3.3M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-5.5M | -7.4M | -771K | -8.6M | -9.1M | -11.7M | -7.8M | -1.5M | 0.0 | 0.0 | -9.9M | -46.2M | -7.1M | -976K | 169.2K | 916.3K | 5.5M | 453.6K | 150.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5M | -4M | -2M | -2M | -12.1M | -9.2M | 29.7M | 0.0 | -434K | 0.0 | -189.9K | 405K | 164.3K | -2K | -1.2K | |
-2.1M | -6.9M | -1.6M | -378K | -378K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-5.8M | -7.7M | -1M | -9.1M | -9.1M | -11.7M | -7.8M | -1.5M | (0.0) | (0.0) | -9.9M | -46.2M | -7.1M | -976.1K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -97K | 0.0 | 0.0 | 505K | 729K | 701K | 1K | 42K | 428K | 596K | 717K | 3.1M | 2.2M | 0.0 | 4.7M | -522.5K | 1.3M | 0.0 | 0.0 | |
-7.6M | -14.4M | -2.4M | -9M | -9M | -12.4M | -11.1M | -3.5M | -2M | -11.7M | -18.5M | -15.8M | -4M | 745.4K | 169.2K | 5.4M | 5.4M | 2M | -1.8K | -1.2K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
402K | -254K | 3K | -461K | -461K | 91K | 10K | 86K | -9K | 251K | -90K | 35K | 92K | 38.5K | -27.9K | -31.8K | 0.0 | 0.0 | 0.0 | 0.0 | |
3.3M | -4.7M | 1.4M | -3M | -3M | 3.3M | 2.2M | 5.2M | 3.6M | -6M | -6.5M | -5.9M | 1.7M | 18.3M | 4.7M | 1M | 411.9K | 36.1K | -67.4K | -4.2M | |
16.9M | 21.6M | 20.2M | 23.2M | 23.2M | 18.8M | 16.7M | 11.5M | 7.9M | 13.9M | 20.4M | 26.3M | 24.6M | 6.4M | 1.6M | 608.8K | 196.9K | 160.8K | 228.1K | 4.4M | |
20.2M | 16.9M | 21.6M | 20.2M | 20.2M | 22.1M | 18.8M | 16.7M | 11.5M | 7.9M | 13.9M | 20.4M | 26.3M | 24.6M | 6.4M | 1.6M | 608.8K | 196.9K | 160.8K | 228.1K | |
10.5M | 10M | 3.8M | 6.4M | 6.4M | 15.6M | 15.3M | 8.6M | 5.5M | 5.4M | 12.1M | 9.9M | 5.6M | 17.1M | 4.5M | -4.5M | -5.5M | -818.1K | -3.2M | -1.1M |
LFVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 13, 2026 | 2026 | |
S-3 S-3 N/A | March 10, 2026 | March 10, 2026 | ย | |
8-K 8-K 2026 N/A | February 04, 2026 | January 30, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Continue your LFVN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.